Petrák Lab
Publications (dedicated to NPU=N or Biocev=B, international collaboration=I, collaboration with hospital=H, from group in Inst.131/from Detached group)
Petrak J, Tevosian SG, Richter S, Ghayee HK. Metabolomics and proteomics in pheochromocytoma and paraganglioma: Translating biochemistry and biology to bedside. Best Pract Res Clin Endocrinol Metab. 2024 Sep 5:101935. doi: 10.1016/j.beem.2024.101935. (IF 6.1) [PubMed] JCR Q1
Majtan T, Olsen T, Sokolova J, Krijt J, Křížková M, Ida T, Ditrói T, Hansikova H, Vit O, Petrak J, Kuchař L, Kruger WD, Nagy P, Akaike T, Kožich V. Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function. Redox Biology. 2024 volume 73; 103222, ISSN 2213-2317. https://doi.org/10.1016/j.redox.2024.103222. (IF 11.4) [Link] JCR Q1
Vít O, Petrák J. Autotaxin and Lysophosphatidic Acid Signalling: the Pleiotropic Regulatory Network in Cancer. Folia Biol (Praha). 2023;69(5-6):149-162. doi:10.14712/fb2023069050149. (IF 1.1) [PubMed] JRC Q4
Benes J, Kroupova K, Kotrc M, Petrak J, Jarolim P, Novosadova V, Kautzner J, Melenovsky V. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Sci Rep. 2023 Sep 25;13(1):16004. doi: 10.1038/s41598-023-42558-4. (IF 18.2) [Pubmed] JCR Q1
Vit O, Talacko P, Musil Z, Hartmann I, Pacak K, Petrak J. Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization. Clin Proteom 20, 39 (2023). https://doi.org/10.1186/s12014-023-09428-7 (IF 3.8) [Link] JCR Q2
Soukup J, Kostelanská M, Kereïche S, Hujacová A, Pavelcová M, Petrák J, Kubala Havrdová E, Holada K. Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. Journal of Clinical Medicine. 2022; 11(10):2832. https://doi.org/10.3390/jcm11102832. (IF 4.964) [PubMed] JCR Q2 / JCI Q1
Jankovska E, Lipcseyova D, Svrdlikova M, Pavelcova M, Kubala Havrdova E, Holada K, Petrak J. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. Int J Neurosci. 2022 Jul;132(7):724-734. doi: 10.1080/00207454.2020.1837801. (IF 2.590) [PubMed] JCR Q4
Vit O, Patel M, Musil Z, Hartmann I, Frysak Z, Miettinen M, Pacak K and Petrak J. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules 2021, 26, 6567. (IF 4.927) [PubMed] (H, I, 131) JCR Q2 / JCI Q3
Havlenova T, Skaroupkova P, Miklovic M, Behounek M, Chmel M, Jarkovska D, Sviglerova J, Stengl M, Kolar M, Novotny J, Benes J, Cervenka L, Petrak J, Melenovsky V. Right versus left ventricular remodeling in heart failure due to chronic volume overload. Sci Rep. 2021 Aug 24;11(1):17136. doi: 10.1038/s41598-021-96618-8. (IF 4.997) [PubMed] (B, H, 131) JCR Q2 / JCI Q1
Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D and Petrak J. Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib. Int. J. Oncol. 58: 238-250, 2021. (IF 5.884) [PubMed] (B, 131) JCR/JCI Q2
Vit O, Harant K, Klener P, Man P, Petrak J. A three-pronged "Pitchfork" strategy enables an extensive description of the human membrane proteome and the identification of missing proteins. J Proteomics. 2019 Jul 30;204:103411. doi: 10.1016/j.jprot.2019.103411. (IF 3.509) [PubMed] (131) JCR Q2 / JCI Q1
Jankovska E, Svitek M, Holada K, Petrak J. Affinity depletion versus relative protein enrichment: a side-by-side comparison of two major strategies for increasing human cerebrospinal fluid proteome coverage. Jankovska E, Svitek M, Holada K, Petrak J. Clin Proteom (2019) 16:9. https://doi.org/10.1186/s12014-019-9229-1. (IF 2.568) [PDF] (N, 131) JCR/JCI Q1
Petrak J, Havlenova T, Krijt M, Behounek M, Franekova J, Cervenka L, Pluhacek T, Vyoral D, Melenovsky V. Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. Biochim Biophys Acta Gen Subj. 2019 Jan 21. pii: S0304-4165(19)30016-9. doi: 10.1016/j.bbagen.2019.01.010. (IF 3.422) [PubMed] (N, H, 131) JCR/JCI Q2
Krijt M, Jirkovska A, Kabickova T, Melenovsky V, Petrak J, Vyoral D. Detection and quantitation of iron in ferritin, transferrin and labile iron pool (LIP) in cardiomyocytes using 55Fe and storage phosphorimaging. BBA-GEN SUBJECTS 1862 (2018) 2895-2901. https://doi.org/10.1016/j.bbagen.2018.09.005. (IF 3.681) [Web] (N, H, 131) JCR/JCI Q2/Q3
Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, Chmel M, Petrak J. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018 Sep 20;43(5):1437-1450. doi: 10.1159/000493657. (IF 2.123) [PDF] (N, H, 131) JCR/JCI Q2/Q3
Melenovsky V, Hlavata K, Sedivy P, Dezortova M, Borlaug BA, Petrak J, Kautzner J, Hajek M. Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure. Circ Heart Fail. 2018;11e004800. doi: 10.1161/CIRCHEARTFAILURE.117.004800. (IF 6.526) [PDF] (N, I, H, 131) JCR/JCI Q1
Zimmermannova O, Doktorova E, Stuchly J, Kanderova V, Kuzilkova D, Strnad H, Starkova J, Alberich-Jorda M, Falkenburg JHF, Trka J, Petrak J, Zuna J, Zaliova M. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene. 2017 Oct 26;36(43):5985-5994. doi: 10.1038/onc.2017.210. (IF 6.854) [PDF] (B, N, H, I, 131) JCR/JCI Q1
Vyoral D, Jiri Petrak. Therapeutic potential of hepcidin - the master regulator of iron metabolism. Pharmacol Res. 2017 Jan;115:242-254. doi: 10.1016/j.phrs.2016.11.010. Review. PubMed PMID: 27867027. (IF 4.897)(B, N, 131) JCR/JCI Q1
Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017 Apr;19(4):522-530. doi: 10.1002/ejhf.640. (IF 10.683) [PDF] (B, N, I, H, 131) JCR/JCI Q1
Vit O, Petrak J. Integral membrane proteins in proteomics. How to break open the black box? J Proteomics. 2017 Feb 5. pii: S1874-3919(16)30361-X. doi: 10.1016/j.jprot.2016.08.006. (IF 3.722) [PDF] (B, 131) JCR Q2 / JCI Q1
Sedmera D, Neckar J, Benes J Jr, Pospisilova J, Petrak J, Sedlacek K, Melenovsky V. Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload. Front Physiol. 2016 Aug 25;7:367. doi: 10.3389/fphys.2016.00367. (IF 4.134) [PDF] (B, H, 131) JCR Q1 / JCI Q2
Large-scale identification of membrane proteins based on analysis of trypsin-protected transmembrane segments. O. Vit, A. Kadek, J. Hausner, J. Sklenar, K. Harant, P. Novak, M. Scigelova, G. Woffendin and J. Petrák. J Proteomics. 2016 Mar 11. pii: S1874-3919(16)30069-0. (IF 3.914) [PDF] (B, I, 131) JCR Q2 / JCI Q1
Toman O, Kabickova T, ViT O, Fiser R, Machova Polakova K, Zach J, Linhartova J, Vyoral D and Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncology Reports, 2016 (in print) (IF 2.662) [PDF] (B, H, 131) JCR Q2 / JCI Q1